Chronic low back pain (LBP) occur without structural causes and are often resistant to conventional analgesic drugs. The number of pharmacological analgesic drugs is available to reduce the LBP, but due to their adverse effects, they are unable to provide sufficient therapeutic effect. Therefore, the results of this research demonstrate that periarticular injection of meloxicam is significantly reduced the LBP and leads to an improvement in the level of physical activity after three months’ follow-up.

Low back pain (LBP) is a condition occurred often and costly to manage. The study involved the estimation of the hypothesis that Meloxicam periradicular injections might improve physical activity and reduce LBP than saline injection at three months’ follow-up.

A total of eighty participants with LBP of <6 months duration were randomized to the Meloxicam or the control after the IRB approval. The case was crossed-over to the other group if the numeric rating score (NRS) at 24 hours remained >50% of the pre-treatment score. The NRS for a successful therapy was <3 at three months’ follow-up. The estimation of physical-assistance, physical-activities limitations, work-absence, and pain-related insomnia were taken as secondary outcomes.

The M group and C group exhibited 9.2 and 9.3 baseline NRS, respectively. After 24hours postoperative follow-up, M group and C group showed 3.5, and 6.3 mean NRS, respectively. C-group exhibited a higher number of cross-over cases. Sixty-six patients allocated in the M-group and 54 reported NRS score <3. Whereas only 14 (9+5) subjects continued in the C-group and 8 patients had NRS <3.

Meloxicam is an efficient analgesic approach for acute/subacute LBP, and its novel use leads to an escalation in the level of physical activity at the three months follow-up.